Barbara Grohmann-Izay

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

Heinz Gisslinger, Christoph Klade, Pencho Georgiev et al. · The Lancet Haematology · 2020 · 347 citations

Pharmacy, Hematology, Pharmacotherapy +5

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo

Emmanuelle Verger, Juliette Soret‐Dulphy, Nabih Maslah et al. · Blood Cancer Journal · 2018 · 55 citations · Full text

Life Sciences, Hematology, Immunology +13

Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in Polycythemia Vera Patients

Heinz Gisslinger, Christoph Klade, Pencho Georgiev et al. · Blood · 2016 · 28 citations

Pharmacy, Pharmacology, Pharmacotherapy +3

Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial

Martin Unger, Andrea Morelli, Mervyn Singer et al. · Trials · 2018 · 23 citations · Full text

Medicine, Pharmacotherapy, Hemodynamic Management +16

Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs. HU/BAT

Heinz Gisslinger, Christoph Klade, Pencho Georgiev et al. · Blood · 2018 · 20 citations

Pharmacy, Hematology, Pharmacotherapy +6